You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The SICILIAN algorithm, which uses statistical modeling to score candidate fusions in single-cell RNA sequencing data, is being used to map splice sites in individual tumor cells.
The in vitro diagnostic test can deliver molecular results from whole blood samples in less than three hours, the company said.
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The researchers plan to develop a clinical test to monitor CML patients in remission for the BCR-ABL1 rearrangement.
Asuragen test kits to detect major and minor BCR-ABL fusions can now run on the Roche Diagnostics Cobas z 480 Analyzer.
The test measures minimal residual disease and can be used to monitor patients eligible for discontinuation of treatment with Tasigna.
The test uses droplet digital PCR to detect BCR-ABL gene fusions and is intended for treatment response monitoring of chronic myeloid leukemia.
The molecular test is now the first FDA-cleared assay to monitor treatment response and disease clearance in chronic myeloid leukemia patients.
Digital PCR can better detect low levels of chronic myeloid leukemia in patients than other PCR-based approaches, according to Imperial College London researchers.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.